Diagnostyka
zł 159.00Change from previous close: 0.00%
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- zł 5.37B
- Enterprise value
- zł 6.59B
- P/E (trailing 12 months)
- 21.1
- Forward P/E
- 15.7
- Price/book
- 10.5
- Price/sales
- 2.08
- EV/EBITDA
- 10.9
- EV/revenue
- 2.55
Profitability and growth
- Gross margin
- 78.6%
- Operating margin
- 13.9%
- Net margin
- 9.9%
- ROE
- 55.4%
- ROA
- 11.8%
- Revenue growth (year over year)
- 16.1%
- Earnings growth (year over year)
- -10.1%
Financial health
- Total cash
- zł 17.56M
- Total debt
- zł 1.22B
- Debt/equity
- 2.32
- Current ratio
- 0.82
- Quick ratio
- 0.70
Dividends
- Annual dividend per share
- zł 4.40
- Dividend yield
- 2.8%
- Payout ratio
- 58.3%
- Ex-dividend date
- June 1, 2026
Analysts and estimates
- Average price target
- zł 196.39
- Median price target
- zł 193.00
- High price target
- zł 215.00
- Low price target
- zł 176.00
- Analysts with a price target
- 7
- Consensus
- Buy
- EPS estimate, current year
- zł 7.81
Shares and trading
- Average volume
- 29.92K
- Shares outstanding
- 33.76M
- Float
- 16.4M
- Institutional ownership
- 16.7%
- Insider ownership
- 47.2%